


PHARMACEUTICAL 2019



VERTEX PHARMACEUTICALS INC MA Rank 4 of 371







PHARMACEUTICAL 2019



VERTEX PHARMACEUTICALS INC MA Rank 4 of 371



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 645% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 391%, being 722% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	3,843,109
Cost of Goods Sold	409,539
Intangible Assets	50,384
Liabilities, Current	1,120,292
Liabilities, Non-Current	26,280
Other Assets	-1,146,859
Other Compr. Net Income	46,144
Other Expenses	-1,458,046
Other Liabilities	664,123
Other Net Income	-34,909
Property and Equipment	812,005
Research and Development	1,416,476
Revenues	3,047,597
Selling, General and Administrative Expense	557,616

Output Variable	Value in 1000 USD
Assets	3,558,639
Liabilities	1,810,695
Expenses	925,585
Stockholders Equity	1,747,944
Net Income	2,087,103
Comprehensive Net Income	2,110,175
Economic Capital Ratio	391%